Private equity firm Keensight says it no longer aims to strike a deal for the British medtech due to the ‘current ...

NIOX Group Plc engages in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNo) worldwide. Its products include NIOX VERO ...

NIOX Group Plc engages in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNo) worldwide. Its products include NIOX VERO ...

The company sold 6.3 million Niox FeNO tests, up 19% from 2023, reflecting growing demand for its asthma diagnostics solutions. During the year, Niox returned £25.2m to shareholders through a £4 ...

Keensight Capital said it won't be making a firm offer for medical device company Niox Group because of the current macroeconomic environment. Last month, the group put forward a 322.4 million ...

Niox Group shares jumped after the medical device company said it received a 322.4 million pound ($419.3 million) takeover proposal from Keensight Capital that it would be prepared to recommend to ...

Private equity firm Keensight Capital has revealed that it will not make a takeover offer for NIOX Group. The specialist healthcare and technology investor, which had around €5.5billion in ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

Niox develops a point-of-care device that measures asthma biomarker fractional exhaled nitric oxide (FeNO). In a brief statement issued on 11 April, Keensight said it no longer intended to make a ...